Advanced Biomed Inc.
ADVBHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. At a $5.2M market cap, Advanced Biomed Inc. ranks as a micro-cap company within healthcare. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells.
Market Cap
$5.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-5.00
EPS (Fwd)
—
ROE
-79.5%
ROA
-21.3%
Cash
$385,535
Total Debt
$1.1M
Free CF
-$12.0M
52W Change
-64.8%
Annual Financials
Cash vs Debt
Where ADVB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ADVB finished 34.18% below its 150-day moving average ($6.32) and 31.69% below its 200-day moving average ($6.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADVB overbought or oversold?
At the October 20, 2026 close, ADVB's RSI(14) was 22.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Advanced Biomed Inc. carries $1.1M in total debt against $386K in cash reserves — debt is roughly 2.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$12.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -79.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Advanced Biomed Inc. and its sector.